Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (15879)	7/15/2002 10:02:26 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Mr Gw, the very cool one, who sees imclowns and elanes all over the place and never see the contingencies. The Amevive the world was seen "months prior to the FDa" was a gloomy non approvable one, despite my claims to the contrary, and even your lovely Fulcrum came after it, just to realize and turn around on time. The Amevive NOW is the SURE approval coming SOON and marketing SOON. Otherwise is your fiction to love Fulcrum strong buy in xoma, but to turn away their reversing sell on Biogen. But, for the voodoo clinical benefits and baxtard multimelons milestones (it seems like mileblockages)believers any fact seems fiction. By the way, The Boa ingested Pharmacia, now they can have Celebrex all for their own, and 3 extra reps per doctor that manages MS patients, they figured out that 3 dinners a week are necessary to give more expensive medications 3 times a week instead of the cheaper once a week. Contingent to further fantasies !!!

To: aknahow who wrote (15879)	7/15/2002 10:08:26 PM
From: Cacaito	Respond to of 17367

Your Flumist example is perfect for Xanelim, incomplete data, clinicals, manufacturing, claims and batches sent back to square one. Either you are demented and do not remember your own jumps when after the Dermatology meetings you were sure they will be first to file and market, and later accusing Biogen of rushing and even the day by day clocking, to find out that Amevive is soon to be approved and market... while Xanelim is still in the figuring out state of looking to see if they can manufacture a working molecule in commercial amounts. Talking about fiction and contingency batches !!!